LIQUIDIA CORP (LQDA)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for LQDA
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| LQDA | Chairperson of our Audit Committee | 74 | ["consultant","managing director and senior advisor for GCA Global, LLC","executive vice president, head of research at Vector Securities, LLC","president of Natwest Securities Limited","executive vice president, head of equity division at Drexel Burnham Lambert, Inc.","Bachelor of Science from the University of Rhode Island","Master of Business Administration from Baruch College","business and financial expertise","experience serving on the boards of directors of several public pharmaceutical and life sciences companies"] | ["Audit Committee","Compensation Committee","Litigation Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| AVIR | Independent Director | 74 | ["Mr. Kirsch brings decades of experience in life science and healthcare finance, particularly M&A advisory and capital raising.","Leadership roles in investment banking overseeing significant strategic transactions and numerous public and private financings.","Current senior advisory role at Alvarez and Marsal.","Public company directorship experience.","Assisting in the buildout of the life science practice at Alvarez and Marsal.","Managing Director/Senior Advisor at GCA Savvian focused on healthcare investment banking activities.","Managing Director at Vector Securities overseeing public and private healthcare financings.","CEO of NatWest Markets managing global securities business."] | ["Audit","Compensation","Nominating and Corporate Governance"] | 2026 |
Biography sourced from the proxy statement filing.
Mr. Kirsch has been a member of our Board, Chairperson of our Audit Committee and a member of our Compensation Committee since Liquidia Corporation s formation in June 2020. Previously, Mr. Kirsch served as a member of our Litigation Committee from August 2020 to January 2022. Mr. Kirsch has been a member of the board of directors of Liquidia Technologies since September 2016, and was the Chairperson of Liquidia Technologies Audit Committee since its formation in August 2016 until consummation of the Merger Transaction (as defined below) in November 2020 and a member of Liquidia Technologies Compensation Committee from May 2019 until November 2020. Mr. Kirsch previously served as a director of POZEN Inc. (Nasdaq: POZN) from May 2004 until February 2016, as a director of Aralez Pharmaceuticals, Inc. (Nasdaq: ARLZ) from February 2016 until May 2019, as a director of Kadmon Corporation (NYSE: KDMN) from May 2019 to November 2021 and as a director of Immunomedics, Inc. (Nasdaq: IMMU) from August 2015 until October 2016. Mr. Kirsch is currently a consultant. From 2005 until 2018, Mr. Kirsch served as a managing director and senior advisor for GCA Global, LLC, a global investment banking firm. From 1994 to 2005, he served as executive vice president, head of research at Vector Securities, LLC, a brokerage firm. From 1990 to 1993, Mr. Kirsch served as president of Natwest Securities Limited, a brokerage firm. From 1979 to 1990, Mr. Kirsch worked at Drexel Burnham Lambert, Inc., an investment banking firm, where he held the position of executive vice president, head of equity division. Mr. Kirsch graduated from the University of Rhode Island with a Bachelor of Science and also holds a Master of Business Administration from Baruch College. We believe Mr. Kirsch is qualified to serve on our Board due to his business and financial expertise and his experience serving on the boards of directors of several public pharmaceutical and life sciences companies.